文献速递消化系统肿瘤

SIRveNIB研究:选择性内放射治疗对比索拉非尼治疗亚太地区肝细胞癌

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
PubMed 文献 · J Clin Oncol · 2018-03-02

SIRveNIB是一项开放标签、研究者发起的III期试验,比较钇-90树脂微球放射栓塞(RE)与索拉非尼800 mg/d在局部晚期肝细胞癌(HCC)患者中的疗效与安全性。共随机分配360例患者(RE组182例,索拉非尼组178例),主要终点总生存(OS)在两组间无显著差异(中位OS 8.8 vs 10.0个月;HR 1.1;95%CI 0.9-1.4;RE组≥3级不良事件发生率显著低于索拉非尼组(27.7% vs 50.6%;

要点

  • RE组严重不良事件发生率更低(20.8% vs 35.2%)。

核心结论

  • 在局部晚期HCC患者中,RE与索拉非尼的总生存无显著差异。
  • RE具有更优的毒性特征,可能有助于特定患者的治疗选择。

研究设计与样本

  • SIRveNIB为开放标签、研究者发起的III期试验,采用优效/劣效双向设计。
  • 纳入亚太地区11个国家的局部晚期HCC患者,按1:1随机分配至RE组(182例)或索拉非尼800 mg/d组(178例),按中心和门静脉癌栓分层。
  • 主要终点为总生存(OS),疗效分析基于意向治疗人群,安全性分析基于治疗人群。

主要发现

  • RE组和索拉非尼组分别有28.6%和9.0%的患者未接受 assigned 治疗,两组间无显著交叉。
  • 共报告1468例治疗中出现的不良事件(RE组437例,索拉非尼组1031例)。
  • 常见≥3级不良事件:腹水(5/130 [3.8%] vs 4/162 [2.5%])、腹痛(3/130 [2.3%] vs 2/162 [1.2%])、贫血(0 vs 4/162 [2.5%])、放射性肝炎(2/130 [1.5%] vs 0)。

临床怎么用

  • 对于局部晚期HCC,RE与索拉非尼的OS相似,但RE的毒性更低,可考虑用于无法耐受索拉非尼毒性的特定患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (90Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment. Patients were randomly assigned 1:1 and stratified by center and presence of portal vein thrombosis. Primary end point was overall survival (OS). Efficacy analyses were performed in the intention-to-treat population and safety analyses in the treated population. Results A total of 360 patients were randomly assigned (RE, 182; sorafenib, 178) from 11 countries in the Asia-Pacific region. In the RE and sorafenib groups, 28.6% and 9.0%, respectively, failed to receive assigned therapy without significant cross-over to either group. Median OS was 8.8 and 10.0 months with RE and sorafenib, respectively (hazard ratio, 1.1; 95% CI, 0.9 to 1.4; P = .36). A total of 1,468 treatment-emergent adverse events (AEs) were reported (RE, 437; sorafenib, 1,031). Significantly fewer patients in the RE than sorafenib group had grade ≥ 3 AEs (36 of 130 [27.7%]) v 82 of 162 [50.6%]; P < .001). The most common grade ≥ 3 AEs were ascites (five of 130 [3.8%] v four of 162 [2.5%] patients), abdominal pain (three [2.3%] v two [1.2%] patients), anemia (zero v four [2.5%] patients), and radiation hepatitis (two [1.5%] v zero [0%] patients). Fewer patients in the RE group (27 of 130 [20.8%]) than in the sorafenib group (57 of 162 [35.2%]) had serious AEs. Conclusion In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib. The improved toxicity profile of RE may inform treatment choice in selected patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018. PMID: 29498924. doi:10.1200/JCO.2017.76.0892

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。